Join Vyant Bio at the 2022 CDKL5 Forum, Hosted by the Loulou Foundation on November 7-8, 2022
Vyant Bio’s Human First Drug Discovery Platform Platform and Poster Presentations Progress on CDKL5 Deficiency Disorder (CDD) Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (CNS) platform integrates machine learning and biology to accelerate…